Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Climb Bio (CLYM) Interest & Investment Income (2022 - 2026)

Climb Bio filings provide 5 years of Interest & Investment Income readings, the most recent being $1.5 million for Q1 2026.

  • Quarterly Interest & Investment Income fell 33.8% to $1.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7.6 million through Mar 2026, down 16.83% year-over-year, with the annual reading at $8.3 million for FY2025, 2.35% up from the prior year.
  • Interest & Investment Income hit $1.5 million in Q1 2026 for Climb Bio, down from $1.8 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $2.8 million in Q3 2024 and bottomed at $147000.0 in Q2 2022.
  • Average Interest & Investment Income over 5 years is $1.5 million, with a median of $1.4 million recorded in 2023.
  • The largest annual shift saw Interest & Investment Income skyrocketed 655.1% in 2023 before it plummeted 33.8% in 2026.
  • Climb Bio's Interest & Investment Income stood at $760000.0 in 2022, then soared by 77.5% to $1.3 million in 2023, then surged by 86.88% to $2.5 million in 2024, then decreased by 27.57% to $1.8 million in 2025, then decreased by 17.09% to $1.5 million in 2026.
  • Per Business Quant, the three most recent readings for CLYM's Interest & Investment Income are $1.5 million (Q1 2026), $1.8 million (Q4 2025), and $2.0 million (Q3 2025).